C2INFORM

Owners

Goods & Services

Providing medical, disease, and cancer testing, detection, analysis, monitoring, and results reporting services, namely, providing medical testing services and information in the field of cancer research and disease classification; structural and functional analysis of genomes, namely, providing and performing genome sequencing of blood samples to health systems, oncologists, physicians, medical professionals, hospitals, and medical, disease, and cancer researchers, centers, clinics, and labs; Blood analysis services, namely, providing information and reports on patient's blood for minimal residual disease (MRD), cancer cells, and genetic-based diseases using whole genome sequencing for use by cancer patients, health systems, oncologists, physicians, medical professionals, hospitals, and medical, disease, and cancer researchers, centers, clinics, and labs; Software-as-a-Service (SaaS) services featuring non-downloadable computer software, non-downloadable computer applications, and web-based non-downloadable software and Platform-as-a-Service (PaaS) services feature computer software platforms in the nature of non-downloadable computer software, non-downloadable computer applications, and web-based non-downloadable software, all for accessing cloud-based servers and remote client servers for providing whole genome sequencing (WGS) medical testing results and reports, pre-surgical and post-surgical disease and cancer burden scores through bioinformatics and artificial intelligence, clinical analysis, and analyzing genetic patterns post-surgery

Providing medical, disease, and cancer testing, detection, analysis, monitoring, and results reporting services, namely, medical testing for diagnostic or treatment purposes, medical analysis services relating to the treatment of patients, medical diagnostic testing, and monitoring and reporting services; medical testing for diagnostic or treatment purposes, namely, providing and performing genome sequencing of blood samples to health systems, oncologists, physicians, medical professionals, hospitals, and medical, disease, and cancer researchers, centers, clinics, and labs for diagnostic or treatment purposes; medical information and diagnostic test reporting services, namely, providing information and reports on patient's blood for minimal residual disease (MRD), cancer cells, and genetic-based diseases using whole genome sequencing for use by cancer patients, health systems, oncologists, physicians, medical professionals, hospitals, and medical, disease, and cancer researchers, centers, clinics, and labs